【摘要】 目的 探讨医师药师联合评估围妊娠期女性用药风险对提高围妊娠期女性用药安全的作用。方法 选取2021年8月至2021年11月安徽医科大学第三附属医院合肥市第一人民医院滨湖院区产前咨询门诊中107例围妊娠期女性用药咨询案例，建立围妊娠期药物暴露登记及妊娠结局随访表，收集并回顾性分析患者基本信息、用药信息、妊娠结局、新生儿结局等；重点追踪使用缺乏安全性数据药物的患者妊娠及新生儿结局；比较接种不同类型新型冠状病毒疫苗（简称新冠疫苗）患者妊娠及新生儿结局。结果107例围妊娠期女性用药咨询中患者平均年龄为（30.58±5.12）岁，人均用药数量为（2.71±2.05）种，使用次数排名前3类药物依次为生物制品（33.89%）、中药（23.89%）、抗感染药物（15.56%）。自患者咨询日起追踪至妊娠终止时间，追踪天数平均为（126.21±57.77）天，共追踪到71例（66.36%）妊娠结局，包括5例（4.67%）自愿选择人工终止妊娠、其中胎儿结构异常1例（0.93%）。重点追踪的45例（42.06%）围妊娠期用药患者妊娠结局良好，新生儿无畸形情况。接种两种不同类型新冠疫苗（灭活疫苗、蛋白亚单位疫苗）的患者在分娩方式、分娩数量及新生儿分娩时胎龄、性别、身长、体质量、Apgar评分及新生儿病理情况方面比较，差异均无统计学意义（P>0.05）。结论 医师药师联合评估围妊娠期用药风险工作，能为患者提供科学和个性化的用药建议与临床指导，便于登记与收集药物围妊娠期使用的循证医学依据。更多还原

【Abstract】 Objective To explore the effect of joint physician-pharmacist assessment of medication risk on improving the safety of peri-pregnancy women’s medication use. Methods The cases of medication consultation for 107 peri-pregnant women in prenatal consultation outpatient of Binhu Hospital from August 2021 to November 2021 were selected. The drug exposure registration and pregnancy outcome follow-up table were established, and the basic information of patients, medication information, pregnancy outcome and neonatal outcome were collected and retrospectively analyzed. Emphasis was placed on tracking pregnancy and newborn outcomes of patients using medications without safety data, and pregnancy and newborn outcomes in patients vaccinated with different types of novel coronavirus vaccine(referred to as COVID-19 vaccine) weer compared. Results The average age of patients in the 107 peri-pregnancy women’s medication counseling was 30.58±5.12 years old, the number of medications per capita was 2.71±2.05, and the top three categories of medications used were, in terms of frequency, biological products(33.89%), traditional Chinese medicines(23.89%), and anti-infective medications(15.56%). From the date of consultation to the pregnancy termination, the average number of tracking days was(126.21±57.77) days, and 71(66.36%) pregnancy outcomes were tracked, 5 cases(4.67%) voluntarily chose artificial termination of pregnancy, including 1 case(0.93%) with abnormal fetal structural abnormalities. Forty-five(42.06%) patients who were focused on tracking perinatal medication had favorable pregnancy outcomes and there was no malformation of newborns. There was no significant difference in delivery mode, delivery number, gestational age, sex, length, weight, the neonatal pathological condition and Apgar score between the patients vaccinated with two different types of COVID-19 vaccines(inactivated vaccine and protein subunit vaccine)(P>0.05). Conclusions By conducting the joint physician-pharmacist assessment of medication risk,scientific and personalized medication suggestions and clinical guidance can be provided for patients, which facilitates the registration and collection of evidence-based medical evidence for perinatal medication, and promotes the establishment of the perinatal medication risk classification system in China.更多还原